KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Other Operating Expenses: 2020-2024

Historic Other Operating Expenses for Moderna (MRNA) over the last 5 years, with Dec 2024 value amounting to $1.5 billion.

  • Moderna's Other Operating Expenses fell 59.73% to $207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 30.17%. This contributed to the annual value of $1.5 billion for FY2024, which is 68.80% down from last year.
  • Moderna's Other Operating Expenses amounted to $1.5 billion in FY2024, which was down 68.80% from $4.7 billion recorded in FY2023.
  • In the past 5 years, Moderna's Other Operating Expenses registered a high of $5.4 billion during FY2022, and its lowest value of $8.0 million during FY2020.
  • In the last 3 years, Moderna's Other Operating Expenses had a median value of $4.7 billion in 2023 and averaged $3.9 billion.
  • As far as peak fluctuations go, Moderna's Other Operating Expenses spiked by 32,612.50% in 2021, and later plummeted by 68.80% in 2024.
  • Moderna's Other Operating Expenses (Yearly) stood at $8.0 million in 2020, then spiked by 32,612.50% to $2.6 billion in 2021, then skyrocketed by 106.95% to $5.4 billion in 2022, then fell by 13.35% to $4.7 billion in 2023, then plummeted by 68.80% to $1.5 billion in 2024.